Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in Idiopathic Pulmonary Fibrosis
NCT04598919Phase 2Active, not recruiting
- Sponsor
- National Jewish Health
- Start
- Nov 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of saracatinib in idiopathic pulmonary fibrosis (IPF), sponsored by National Jewish Health. Started Nov 2020; status: active, not recruiting.
02
Drugs
saracatinib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04598919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598919.